Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, will today present its strategy to seize an unprecedented market opportunity during the coming ‘golden decade’ at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Richard Saynor is scheduled to speak on January 13, 2026, at 18:45 CET (9:45 PST), highlighting the company’s consistent progress since becoming an independent entity in 2023 and its unique position as a ‘pure-play’ biosimilar and generic company.
Saynor will emphasize that Sandoz is on track to capture significant share of the more than USD 600 billion in medicines expected to lose exclusivity over the next decade. The generic opportunity alone is valued at USD 340 billion, with Sandoz’s pipeline of over 400 assets targeting nearly two-thirds of that total. The biosimilar opportunity is similarly sized at USD 322 billion, and Sandoz is targeting approximately 60 percent of that market.
In its first two years as a standalone company, Sandoz has delivered on key strategic milestones, including breaking ground on a major sterile biosimilars production center in Brnik, Slovenia, as part of a multi-site project with a total investment exceeding USD 1.1 billion. The company also completed the acquisition of Just-Evotec Biologics’ site in Toulouse, France, and consistently launched new products, with six biosimilar launches in 2025 alone. Additionally, Sandoz opened a new facility for penicillin active ingredients and a new production line, completing a USD 250 million investment in its European antibiotic production network.
Sandoz’s global leadership is built on three pillars: scale, with 1,300 products supplied to over 100 countries; unique positioning as the only pure-play biosimilar and generic company; and a respected leadership team backed by more than 20,000 employees. The company’s strong financial momentum supports its mid-term outlook of mid-single digit annual sales growth to 2028 at constant exchange rates, with core EBITDA margin expansion forecasted to reach 24% to 26% in 2028.
A key focus for Sandoz is addressing the ‘biosimilar void,’ where more than 50 biologics facing loss of exclusivity in the next seven years have no biosimilar planned due to high clinical development costs. Sandoz is leading industry efforts to streamline biosimilar development, which could substantially decrease both cost and time to market without compromising quality, safety, or efficacy.
Saynor concluded: “We are the global leader in an attractive, growing and system-critical market. We are poised to seize the unprecedented market opportunity over the next decade, in the interests of our shareholders, our customers, our partners and most importantly our patients. If we continue to deliver on our promises the way we have to date, we will lead the way in making the next 10 years the ‘golden decade’ of affordable healthcare.”
A webcast of the presentation will be available at https://www.sandoz.com, and presentation slides will be posted after the event.
